Anterior-pituitary function before and after transsphenoidal microsurgery for pituitary tumors

  • Andrea Manni
  • Baha’Uddin M. Arafah
  • Jerald S. Brodkey
  • Olof H. Pearson
Part of the Cancer Treatment and Research book series (CTAR, volume 20)


The introduction of transsphenoidal microsurgery represents a major improvement in the surgical management of functioning and non-functioning pituitary tumors. A distinct advantage of this technique is the ability to achieve selective tumor removal with preservation of normal pituitary tissue, especially in patients with small adenomas. Numerous reports in the literature have underscored the success of transsphenoidal surgery in correcting the hypersecretion of prolactin [1], growth hormone [2], and ACTH [3] due to a functioning pituitary adenoma. As it might be expected, the success of the surgery has been found to be inversely related to the size of the tumor, with the best results obtained in patients with microadenomas (i.e. <10 mm in diameter).


Growth Hormone Pituitary Tumor Serum Prolactin Pituitary Function Transsphenoidal Surgery 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Post, KD, Biler BJ, Adelman LS, Molitch ME, Wolpert SM, Reichlin S: Selective transsphenoidal adenomectomy in women with galactorrhea-amenorrhea. JAMA 242: 158–162, 1979.PubMedCrossRefGoogle Scholar
  2. 2.
    Arafah BM, Brodkey JS, Kaufman B, Velasco M, Manni A, Pearson OH: Transsphenoidal microsurgery in the treatment of acromegaly and gigantism. J Clin Endocrinol Metab 50: 578–585, 1980.PubMedCrossRefGoogle Scholar
  3. 3.
    Tyrrel JB, Brooks RM, Fitzgerald PA, Cofoid PB, Forsham PH, Wilson CB: Cushing’s disease: selective trans-sphenoidal resection of pituitary microadenomas. N Engl J Med 298: 753–758, 1978.CrossRefGoogle Scholar
  4. 4.
    Franks S, Jacobs HS, Martin N, Nabarro JDM: Hyperprolactinemia and impotence. Clin Endocrinol (Oxf) 8: 277–287, 1978.CrossRefGoogle Scholar
  5. 5.
    Bohnet HG, Dahlen HG, Wuttke W, Schneider HPG: Hyperprolatinemic anovulatory syndrome. J Clin Endocrinol Metab 42: 132–143, 1976.PubMedCrossRefGoogle Scholar
  6. 6.
    Jacobs HS: Prolactin and amenorrhea. N Engl J Med 295: 954–956, 1976.PubMedCrossRefGoogle Scholar
  7. 7.
    Arafah BM, Manni A, Brodkey JS, Kaufman B, Velasco M, Pearson OH: Cure of hypogonadism after removal of prolactin-secreting adenomas in men. J Clin Endocrinol Metab 52: 91–94, 1981.PubMedCrossRefGoogle Scholar
  8. 8.
    Thorner MO, Besser GM: Bromocriptine treatment of hyperprolactinaemic hypogonadism. Acta Endocrinologica [Suppl 216] 88: 131–146, 1978.Google Scholar
  9. 9.
    St. George Tucker H, Grubb SR, Wigand JP, Watlington CO, Blackard WG, Becker DP: The treatment of acromegaly by transsphenoidal surgery. Arch Intern Med 140: 795–802, 1980.CrossRefGoogle Scholar
  10. 10.
    Atkinson RL, Becker DP, Martins AN, Schaaf M, Dimond RC, Wartofsky L, Earll JM: Acromegaly. Treatment by transsphenoidal microsurgery 233: 1279–1283, 1975.Google Scholar
  11. 11.
    Hardy J, Somma M, Vezina JL: Treatment of acromegaly: radiation or surgery. In: Current Controversies in Neurosurgery, Moley TP (ed). W.B. Sanders, 1976, pp 377–391.Google Scholar
  12. 12.
    McLanahan CS, Christy JH, Tindall GT: Anterior-pituitary function before and after transsphenoidal microsurgical resection of pituitary tumors. Neurosurgery 3: 142–145, 1978.CrossRefGoogle Scholar
  13. 13.
    Samaan NA, Leavens ME, Jesse RH: Serum growth hormone and prolactin response to thyrotropin-releasing hormone in patients with acromegaly before and after surgery. J Clin Endocrinol Metab 38: 957–963, 1974.PubMedCrossRefGoogle Scholar
  14. 14.
    Frantz AG, Rabkin MT: Effects of estrogen and sex difference on secretion of human growth hormone. J Clin Endocrinol Metab 25: 1470–1480, 1965.PubMedCrossRefGoogle Scholar
  15. 15.
    Spellacy WN, Carlson KL, Schade SL: Human growth hormone levels in normal subjects receiving an oral contraceptive. JAMA 202: 451–454, 1967.PubMedCrossRefGoogle Scholar
  16. 16.
    Sternberger LA: Immunocytochemistry. New York: John Wiley and Sons, 1979.Google Scholar
  17. 17.
    Tolis G, Goldstein M, Friesen HG: Functional evaluation of prolactin secretion in patients with hypothalamic pituitary disorders. J Clin Invest 52: 783–788, 1973.PubMedCrossRefGoogle Scholar
  18. 18.
    Woolf PD, Jacobs LS, Donofrio RV, Borday SZ, Schalch DS: Secondary hypopituitarism; evidence for continuing regulation of hormone release. J Clin Endocrinol Metab 38: 71–76, 1974.PubMedCrossRefGoogle Scholar
  19. 19.
    Costom BH, Grumbach MM, Kaplin SL: Effect of thyrotropin-releasing factor on serum thyroid stimulating hormone. J Clin Invest 50: 2219–2225, 1971.PubMedCrossRefGoogle Scholar
  20. 20.
    Foley TP, Owings J, Hayford JT, Blizzard RM: Serum thyrotropin responses to synthetic thyrotropin-releasing hormone in normal children and hypopituitary patients. J Clin Invest 51: 431–437, 1972.PubMedCrossRefGoogle Scholar
  21. 21.
    Faglia G, Beck-Peccoz P, Ferrari C, Ambrosi B, Spada A, Travaglini P. Paracchi S: Plasma thyrotropin response to thyrotropin-releasing hormone in patients with pituitary and hypothalamic disorders. J Clin Endocrinol Metab 37: 595–601, 1973.PubMedCrossRefGoogle Scholar
  22. 22.
    Robinson AG, Verbalis JG, Nelson PB: Reversible hypopituitarism following carotid artery aneurysm resection. 63rd Annual Meeting of the Endocrine Society, Cincinnati, Ohio, 1981, p 375.Google Scholar
  23. 23.
    Daniel PM, Treip CS: The regenerative capacity of pars distalis of the pituitary gland. In: The Pituitary Gland, vol 2, Harris GW, Donovan BJ (eds), 1966.Google Scholar

Copyright information

© Martinus Nijhoff Publishers, Boston 1984

Authors and Affiliations

  • Andrea Manni
  • Baha’Uddin M. Arafah
  • Jerald S. Brodkey
  • Olof H. Pearson

There are no affiliations available

Personalised recommendations